Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 11 (2011), Pages 2124-2135
http://dx.doi.org/10.1100/2011/380236
Research Article

Advantages and Disadvantages of Hyperbaric Oxygen Treatment in Mice with Obesity Hyperlipidemia and Steatohepatitis

1Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
2Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan
3Department of Japanese Oriental Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
4Institute for Animal Reproduction, 1103 Fukaya, Kasumigaura-shi, Ibaraki 300-0134, Japan
5Faculty of Pharmacy, Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo 202-8585, Japan
6School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
7Department of Hyperbaric Medicine and Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan

Received 30 August 2011; Accepted 15 October 2011

Academic Editors: M. Elisaf and E. Macken

Copyright © 2011 Koichi Tsuneyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Guize, B. Pannier, F. Thomas, K. Bean, B. Jégo, and A. Benetos, “Recent advances in metabolic syndrome and cardiovascular disease,” Archives of Cardiovascular Diseases, vol. 101, no. 9, pp. 577–583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Cornier, D. Dabelea, T. L. Hernandez et al., “The metabolic syndrome,” Endocrine Reviews, vol. 29, no. 7, pp. 777–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. D. Berk, “Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome,” Hepatology, vol. 48, no. 5, pp. 1362–1376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, no. 2, pp. S99–S112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Clark, “The epidemiology of nonalcoholic fatty liver disease in adults,” Journal of Clinical Gastroenterology, vol. 40, supplement 1, pp. S5–S10, 2006. View at Publisher · View at Google Scholar
  6. M. M. Yeh and E. M. Brunt, “Pathology of nonalcoholic fatty liver disease,” American Journal of Clinical Pathology, vol. 128, no. 5, pp. 837–847, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. D'Agostino Dias, B. Fontes, R. S. Poggetti, and D. Birolini, “Hyperbaric oxygen therapy: types of injury and number of sessions—a review of 1506 cases,” Undersea & Hyperbaric Medicine, vol. 35, no. 1, pp. 53–60, 2008. View at Google Scholar · View at Scopus
  8. K. C. Huang, W. H. Hsu, K. T. Peng, T. J. Huang, and R. W. W. Hsu, “Hyperbaric oxygen therapy in orthopedic conditions: an evaluation of safety,” Journal of Trauma, vol. 61, no. 4, pp. 913–917, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kawashima, H. Tamura, I. Nagayoshi, K. Takao, K. Yoshida, and T. Yamaguchi, “Hyperbaric oxygen therapy in orthopedic conditions,” Undersea and Hyperbaric Medicine, vol. 31, no. 1, pp. 155–162, 2004. View at Google Scholar · View at Scopus
  10. G. Germain, J. Delaney, G. Moore, P. Lee, V. Lacroix, and D. Montgomery, “Effect of hyperbaric oxygen therapy on exercise-induced muscle soreness,” Undersea and Hyperbaric Medicine, vol. 30, no. 2, pp. 135–145, 2003. View at Google Scholar · View at Scopus
  11. S. Babul and E. C. Rhodes, “The role of hyperbaric oxygen therapy in sports medicine,” Sports Medicine, vol. 30, no. 6, pp. 395–403, 2000. View at Google Scholar · View at Scopus
  12. S. Y. Chen, Y. C. Chen, J. K. Wang et al., “Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB × NZW) F1 mice,” Clinical Immunology, vol. 108, no. 2, pp. 103–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. C. Chen, S. Y. Chen, P. S. Ho et al., “Apoptosis of T-leukemia and B-myeloma cancer cells induced by hyperbaric oxygen increased phosphorylation of p38 MAPK,” Leukemia Research, vol. 31, no. 6, pp. 805–815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Kamada, T. Takehara, and N. Hayashi, “Adipocytokines and liver disease,” Journal of Gastroenterology, vol. 43, no. 11, pp. 811–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Murano, G. Barbatelli, V. Parisani et al., “Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice,” Journal of Lipid Research, vol. 49, no. 7, pp. 1562–1568, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. J. Strissel, Z. Stancheva, H. Miyoshi et al., “Adipocyte death, adipose tissue remodeling, and obesity complications,” Diabetes, vol. 56, no. 12, pp. 2910–2918, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Unfirer, A. Kibel, and I. Drenjancevic-Peric, “The effect of hyperbaric oxygen therapy on blood vessel function in diabetes mellitus,” Medical Hypotheses, vol. 71, no. 5, pp. 776–780, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. N. S. Al-Waili, G. J. Butler, J. Beale et al., “Influences of hyperbaric oxygen on blood pressure, heart rate and blood glucose levels in patients with diabetes mellitus and hypertension,” Archives of Medical Research, vol. 37, no. 8, pp. 991–997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Yasuda, N. Aoki, T. Adachi et al., “Hyperbaric exposure with high oxygen concentration inhibits growth-associated increase in the glucose level of diabetic Goto-Kakizaki rats,” Diabetes, Obesity and Metabolism, vol. 8, no. 6, pp. 714–715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Nomoto, K. Tsuneyama, H. Takahashi, Y. Murai, and Y. Takano, “Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease,” Applied Immunohistochemistry and Molecular Morphology, vol. 16, no. 1, pp. 71–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Kadokawa, K. Ohba, K. Omagari et al., “Intracellular balance of oxidative stress and cytoprotective molecules in damaged interlobular bile ducts in autoimmune hepatitis and primary biliary cirrhosis: in situ detection of 8-hydroxydeoxyguanosine and glutathione-S-transferase-pi,” Hepatology Research, vol. 37, no. 8, pp. 620–627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. V. M. Victor and M. De La Fuente, “Several functions of immune cells in mice changed by oxidative stress caused by endotoxin,” Physiological Research, vol. 52, no. 6, pp. 789–796, 2003. View at Google Scholar · View at Scopus
  23. M. Nagata, W. Suzuki, S. Iizuka et al., “Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate,” Experimental Animals, vol. 55, no. 2, pp. 109–115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Nakanishi, K. Tsuneyama, M. Fujimoto et al., “Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia,” Journal of Autoimmunity, vol. 30, no. 1-2, pp. 42–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Sasaki, W. Suzuki, T. Shimada et al., “Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice,” Life Sciences, vol. 85, no. 13-14, pp. 490–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Copaci, L. Micu, and M. Voiculescu, “The role of cytokines in non-alcoholic steatohepatitis. A systematic review,” Journal of Gastrointestinal and Liver Diseases, vol. 15, no. 4, pp. 363–373, 2006. View at Google Scholar · View at Scopus
  28. N. Rafiq and Z. M. Younossi, “Effects of weight loss on nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 28, no. 4, pp. 427–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Cave, I. Deaciuc, C. Mendez et al., “Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition,” Journal of Nutritional Biochemistry, vol. 18, no. 3, pp. 184–195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. G. P. Aithal, J. A. Thomas, P. V. Kaye et al., “Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis,” Gastroenterology, vol. 135, no. 4, pp. 1176–1184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Fujimoto, K. Tsuneyama, M. Kainuma et al., “Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver,” Experimental Biology and Medicine, vol. 233, no. 3, pp. 328–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Balas, R. Belfort, S. A. Harrison et al., “Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 47, no. 4, pp. 565–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Reboul, S. Thap, F. Tourniaire et al., “Differential effect of dietary antioxidant classes (carotenoids, polyphenols, vitamins C and E) on lutein absorption,” British Journal of Nutrition, vol. 97, no. 3, pp. 440–446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. K. J. Anderson, S. S. Teuber, A. Gobeille, P. Cremin, A. L. Waterhouse, and F. M. Steinberg, “Walnut polyphenolics inhibit in vitro human plasma and LDL oxidation,” Journal of Nutrition, vol. 131, no. 11, pp. 2837–2842, 2001. View at Google Scholar · View at Scopus